The prognostic significance of c-myc oncogene expression in uveal melanoma

Melanoma Research

Volumn 8, Issue 2, 1998, Pages 139-144

  Chana, J S ^a   Cree, I A ^b   Foss, A J E ^c   Hungerford, J L ^d   Wilson, G D ^e  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

^d ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^e Gray Laboratory   (United Kingdom)

Author keywords

C myc oncogene; C myc oncoprotein; Flow cytometry; Prognosis; Uveal melanoma

Indexed keywords

ARTICLE; CANCER LOCALIZATION; CANCER SURVIVAL; HUMAN; HUMAN TISSUE; MELANOMA; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN EXPRESSION; UVEA TUMOR;

EID: 0031896516     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199804000-00006     Document Type: Article

References (24)

1. Evan GI, Littlewood TD. The role of c-myc in cell growth. Curr Opin Gen Dev 1993; 3: 44-49.
2. Lu X, Park SH, Thompson TC, Lane DP. ras-induced hyperplasia occurs with muation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 1992; 70: 153-161.
3. Sisley K, Cottam DW, Rennie IG, Parsons MA, Potter AM, Potter CW, et al. Non-random abnormalities of chromosomes 3, 6, and 8 associated with posterior uveal melanoma. Genes Chromosomes Cancer 1992; 5(3): 197-200.
4. Mooy CM, Luyten GP, de Jong PT, Luider TM, Stijnen T, van de Ham F, et al. Immunohistochemical and prognostic analysis of apoptosis and proliferation in uveal melanoma. Am J Pathol 1995; 147(4): 1097-1104.
5. Riou GF. Proto-oncogenes and prognosis in early carcinoma of the uterine cervix. Cancer Surv 1988; 7: 442-455.
6. Field JK, Spandidos DA, Stell PM, Vaughan ED, Evan GI, Moore JP. Elevated expression of c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma. Oncogene 1989; 4: 1463-1468.
7. Grover R, Ross DA, Sanders R, Wilson GD. C-myc oncoprotein, an independent prognostic marker for intermediate thickness primary melanoma. Plast Reconstr Surg, in press.
8. Grover R, Ross DA, Wilson GD, Sanders R. Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma. Br J Plast Surg 1997; 50: 478-482.
9. Grobbelaar AO, Grover R, Chana JS, Hudson DA, Wilson GD, Sanders R. The clinical significance of c-myc oncogene expression in subungual and plantar melanoma. Melanoma Res 1997; 7(1): 6.
10. Grover R, Grobbelaar AO, Hudson DA, Forder M, Wilson GD, Sanders R. The clinical significance of oncogene expression in subungual melanoma. Br J Plast Surg 1997; 50(1): 15-19.
11. Paul EV, Parnell L, Fraker M. Prognosis of malignant melanoma of the choroid and ciliary body. Int Ophthalmol Clin 1962; 2: 387-402.
12. Hungerford JL. Management of ocular melanoma. Br Med Bull 1995; 51(3): 694-716.
13. Hungerford J. Prognosis in ocular melanoma. Br J Ophthalmol 1989; 73(9): 689-690.
14. Hedley DW, Friedlander ML, Taylor IW, Rugg CA, Musgrove EA. Method for analysis of cellular DNA content of paraffin embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-1335.
15. Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
16. Ross DA, Wilson DG. C-myc expression in cutaneous melanoma: a new prognostic marker. Br J Surg 1998; 85: 46-51.
17. Watson JV, Srewart J, Evan GI, Ritson A, Sikora K. The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. Br J Cancer 1986; 53: 331-337.
18. Rabbitts PH, Watson JV, Lamond A, et al. Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. Embo J 1985; 4: 2009.
19. Berns EMJJ, Klijn JGM, van Putten WLJ, van Staveren IL, et al. C-myc amplification is a better prognostic factor than Her2/neu amplification in primary breast cancer. Cancer Res 1992; 52: 1107-1113.
20. Masters JRW, Vesey SG, Munn CF, et al. C-myc oncoprotein levels in bladder cancer. Urol Res 1998; 16: 341-344.
21. 1. Nature 1987; 328: 445-449.
22. Grover R, Ross DA, Richman PI, Robinson B, Wilson GD. C-myc oncogene expression in human melanoma and its relationship with tumour antigenicity. Eur J Surg Oncol 1996; 22(4): 342-346.
23. Versteeg R, Kruse Wolters KM, Plomp AC, van Leeuwen A, Stam NJ, Ploegh HL, et al. Suppression of class I human histocompatibility leukocyte antigen by c-myc is locus specific. J Exp Med 1989; 170(3): 621-635.
24. Blom DJ, Luyten GP, Mooy CM, Kerkvliet S, Zwinderman AH, Jager MJ. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci 1997; 38: 1865-1872.